A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Nataliya Volodymyrivna Uboha, Yvonne M. Saenger, Olatunji B. Alese, Dae Won Kim, Lei Zheng, Jorge Chaves, Siqing Fu, Jun Gong, Zhaohui Jin, John D. Powderly, Nashat Gabrail, Tanios S. Bekaii-Saab, Angela Tatiana Alistar, Christopher Chen, Laura Agensky, Apollina Goel, Steven Margossian, Steven N Quayle, Matteo Levisetti, J. Eva Selfridge
Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Winship Cancer Institute, Moffitt Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Northwest Medical Specialties, The University of Texas MD Anderson Cancer Center, Cedars-Sinai Medical Center, Mayo Clinic, Carolina BioOncology Institute, Gabrail Cancer Center, Mayo Clinic in Arizona, Atlantic Health System, Stanford Medicine, Stanford University, University Hospitals Seidman Cancer Center, Case Western Reserve University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4399737282